Thymalfasin in the treatment of hepatitis B and C
Thymalfasin exhibited an immunomodulatory and a direct antiviral mechanism of action. The low rate of sustained response of chronic hepatitis with current therapies, underscores the need for new therapeutic options. It has been suggested that thymalfasin may have efficacy in the treatment of chronic...
Gespeichert in:
| Veröffentlicht in: | Annals of the New York Academy of Sciences 2010-05, Vol.1194 (1), p.141-146 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 146 |
|---|---|
| container_issue | 1 |
| container_start_page | 141 |
| container_title | Annals of the New York Academy of Sciences |
| container_volume | 1194 |
| creator | Ciancio, A. Rizzetto, M. |
| description | Thymalfasin exhibited an immunomodulatory and a direct antiviral mechanism of action. The low rate of sustained response of chronic hepatitis with current therapies, underscores the need for new therapeutic options. It has been suggested that thymalfasin may have efficacy in the treatment of chronic hepatitis B and C. Pilots studies in patients with chronic hepatitis B treated with thymalfasin in combination with interferon or nucleoside analogue, showed a 70% complete sustained response rate. Studies in chronic hepatitis C patients, would indicate that thymalfasin in combination with standard or pegylated interferon with ribavirin may improve response rate in hepatitis C virus (HCV) naïve and nonresponder patients. However, a large phase‐III randomized study conducted in Europe in HCV patients nonresponder to Peg‐interferon with ribavirin, demonstrated that thymalfasin did not improve the rate of sustained virologic responses, but, in patients who completed therapy, thymalfasin significantly diminished the relapse rate. In conclusion, thymalfasin, in combination with the standard of care, may be helpful as an adjuvant in the treatment of patients with chronic hepatitis B and C. |
| doi_str_mv | 10.1111/j.1749-6632.2010.05487.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_746085700</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>746085700</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4677-a24a563486fe7b98b857945447b3991b0b85c2507f58a06e7498aef98808b3fe3</originalsourceid><addsrcrecordid>eNqNkMtKAzEUhoMotlZfQQZcuJqa-2UjaNGqVEWsiKtDpmbo1LnUyRTbtzdjtQs3GgIJyXf-k3wIRQT3SRgnsz5R3MRSMtqnOJxiwbXqL7dQd3OxjboYKxVrQ1kH7Xk_w5hQzdUu6lAsmOSSdhEZT1eFzVPrszIKs5m6qKmdbQpXNlGVRlM3t03WZD46j2z5Gg320U5qc-8Ovtceerq8GA-u4tH98HpwNoonXIa2lnIrJONapk4lRidaKMMF5yphxpAEh4MJFVilQlssXXi2ti41WmOdsNSxHjpe587r6n3hfANF5icuz23pqoUHxSUOmRj_TTJGNTWSBfLoFzmrFnUZvgFECKYkMUoGSq-pSV15X7sU5nVW2HoFBEPrH2bQaoZWM7T-4cs_LEPp4XeDRVK4103hj_AAnK6Bjyx3q38Hw93L2WO7DQHxOiDzjVtuAmz9BlIxJeD5bgj8xlyJ29EYHtgnUiafOA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1553761976</pqid></control><display><type>article</type><title>Thymalfasin in the treatment of hepatitis B and C</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Ciancio, A. ; Rizzetto, M.</creator><creatorcontrib>Ciancio, A. ; Rizzetto, M.</creatorcontrib><description>Thymalfasin exhibited an immunomodulatory and a direct antiviral mechanism of action. The low rate of sustained response of chronic hepatitis with current therapies, underscores the need for new therapeutic options. It has been suggested that thymalfasin may have efficacy in the treatment of chronic hepatitis B and C. Pilots studies in patients with chronic hepatitis B treated with thymalfasin in combination with interferon or nucleoside analogue, showed a 70% complete sustained response rate. Studies in chronic hepatitis C patients, would indicate that thymalfasin in combination with standard or pegylated interferon with ribavirin may improve response rate in hepatitis C virus (HCV) naïve and nonresponder patients. However, a large phase‐III randomized study conducted in Europe in HCV patients nonresponder to Peg‐interferon with ribavirin, demonstrated that thymalfasin did not improve the rate of sustained virologic responses, but, in patients who completed therapy, thymalfasin significantly diminished the relapse rate. In conclusion, thymalfasin, in combination with the standard of care, may be helpful as an adjuvant in the treatment of patients with chronic hepatitis B and C.</description><identifier>ISSN: 0077-8923</identifier><identifier>EISSN: 1749-6632</identifier><identifier>DOI: 10.1111/j.1749-6632.2010.05487.x</identifier><identifier>PMID: 20536462</identifier><identifier>CODEN: ANYAA9</identifier><language>eng</language><publisher>Malden, USA: Blackwell Publishing Inc</publisher><subject>Adjuvants, Immunologic - genetics ; Adjuvants, Immunologic - therapeutic use ; Antiviral Agents - administration & dosage ; Antiviral Agents - immunology ; Antiviral Agents - therapeutic use ; antiviral treatment ; chronic hepatitis ; Europe ; Hepacivirus - genetics ; Hepacivirus - immunology ; Hepatitis B - drug therapy ; Hepatitis B - genetics ; Hepatitis B - immunology ; hepatitis B virus ; Hepatitis B, Chronic - drug therapy ; Hepatitis B, Chronic - genetics ; Hepatitis B, Chronic - immunology ; Hepatitis C virus ; Hepatitis C, Chronic - drug therapy ; Hepatitis C, Chronic - genetics ; Hepatitis C, Chronic - immunology ; Humans ; Interferons - genetics ; Interferons - immunology ; Interferons - therapeutic use ; Polyethylene Glycols - administration & dosage ; Polyethylene Glycols - therapeutic use ; Polymerase Chain Reaction ; Ribavirin - administration & dosage ; Ribavirin - therapeutic use ; thymalfasin ; Thymosin - analogs & derivatives ; Thymosin - therapeutic use ; Viral Vaccines - genetics ; Viral Vaccines - immunology ; Viral Vaccines - therapeutic use</subject><ispartof>Annals of the New York Academy of Sciences, 2010-05, Vol.1194 (1), p.141-146</ispartof><rights>2010 New York Academy of Sciences</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4677-a24a563486fe7b98b857945447b3991b0b85c2507f58a06e7498aef98808b3fe3</citedby><cites>FETCH-LOGICAL-c4677-a24a563486fe7b98b857945447b3991b0b85c2507f58a06e7498aef98808b3fe3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1749-6632.2010.05487.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1749-6632.2010.05487.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20536462$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ciancio, A.</creatorcontrib><creatorcontrib>Rizzetto, M.</creatorcontrib><title>Thymalfasin in the treatment of hepatitis B and C</title><title>Annals of the New York Academy of Sciences</title><addtitle>Ann N Y Acad Sci</addtitle><description>Thymalfasin exhibited an immunomodulatory and a direct antiviral mechanism of action. The low rate of sustained response of chronic hepatitis with current therapies, underscores the need for new therapeutic options. It has been suggested that thymalfasin may have efficacy in the treatment of chronic hepatitis B and C. Pilots studies in patients with chronic hepatitis B treated with thymalfasin in combination with interferon or nucleoside analogue, showed a 70% complete sustained response rate. Studies in chronic hepatitis C patients, would indicate that thymalfasin in combination with standard or pegylated interferon with ribavirin may improve response rate in hepatitis C virus (HCV) naïve and nonresponder patients. However, a large phase‐III randomized study conducted in Europe in HCV patients nonresponder to Peg‐interferon with ribavirin, demonstrated that thymalfasin did not improve the rate of sustained virologic responses, but, in patients who completed therapy, thymalfasin significantly diminished the relapse rate. In conclusion, thymalfasin, in combination with the standard of care, may be helpful as an adjuvant in the treatment of patients with chronic hepatitis B and C.</description><subject>Adjuvants, Immunologic - genetics</subject><subject>Adjuvants, Immunologic - therapeutic use</subject><subject>Antiviral Agents - administration & dosage</subject><subject>Antiviral Agents - immunology</subject><subject>Antiviral Agents - therapeutic use</subject><subject>antiviral treatment</subject><subject>chronic hepatitis</subject><subject>Europe</subject><subject>Hepacivirus - genetics</subject><subject>Hepacivirus - immunology</subject><subject>Hepatitis B - drug therapy</subject><subject>Hepatitis B - genetics</subject><subject>Hepatitis B - immunology</subject><subject>hepatitis B virus</subject><subject>Hepatitis B, Chronic - drug therapy</subject><subject>Hepatitis B, Chronic - genetics</subject><subject>Hepatitis B, Chronic - immunology</subject><subject>Hepatitis C virus</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Hepatitis C, Chronic - genetics</subject><subject>Hepatitis C, Chronic - immunology</subject><subject>Humans</subject><subject>Interferons - genetics</subject><subject>Interferons - immunology</subject><subject>Interferons - therapeutic use</subject><subject>Polyethylene Glycols - administration & dosage</subject><subject>Polyethylene Glycols - therapeutic use</subject><subject>Polymerase Chain Reaction</subject><subject>Ribavirin - administration & dosage</subject><subject>Ribavirin - therapeutic use</subject><subject>thymalfasin</subject><subject>Thymosin - analogs & derivatives</subject><subject>Thymosin - therapeutic use</subject><subject>Viral Vaccines - genetics</subject><subject>Viral Vaccines - immunology</subject><subject>Viral Vaccines - therapeutic use</subject><issn>0077-8923</issn><issn>1749-6632</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkMtKAzEUhoMotlZfQQZcuJqa-2UjaNGqVEWsiKtDpmbo1LnUyRTbtzdjtQs3GgIJyXf-k3wIRQT3SRgnsz5R3MRSMtqnOJxiwbXqL7dQd3OxjboYKxVrQ1kH7Xk_w5hQzdUu6lAsmOSSdhEZT1eFzVPrszIKs5m6qKmdbQpXNlGVRlM3t03WZD46j2z5Gg320U5qc-8Ovtceerq8GA-u4tH98HpwNoonXIa2lnIrJONapk4lRidaKMMF5yphxpAEh4MJFVilQlssXXi2ti41WmOdsNSxHjpe587r6n3hfANF5icuz23pqoUHxSUOmRj_TTJGNTWSBfLoFzmrFnUZvgFECKYkMUoGSq-pSV15X7sU5nVW2HoFBEPrH2bQaoZWM7T-4cs_LEPp4XeDRVK4103hj_AAnK6Bjyx3q38Hw93L2WO7DQHxOiDzjVtuAmz9BlIxJeD5bgj8xlyJ29EYHtgnUiafOA</recordid><startdate>201005</startdate><enddate>201005</enddate><creator>Ciancio, A.</creator><creator>Rizzetto, M.</creator><general>Blackwell Publishing Inc</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QG</scope><scope>7QL</scope><scope>7QP</scope><scope>7QR</scope><scope>7ST</scope><scope>7T5</scope><scope>7T7</scope><scope>7TK</scope><scope>7TM</scope><scope>7TO</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>SOI</scope><scope>7X8</scope></search><sort><creationdate>201005</creationdate><title>Thymalfasin in the treatment of hepatitis B and C</title><author>Ciancio, A. ; Rizzetto, M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4677-a24a563486fe7b98b857945447b3991b0b85c2507f58a06e7498aef98808b3fe3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adjuvants, Immunologic - genetics</topic><topic>Adjuvants, Immunologic - therapeutic use</topic><topic>Antiviral Agents - administration & dosage</topic><topic>Antiviral Agents - immunology</topic><topic>Antiviral Agents - therapeutic use</topic><topic>antiviral treatment</topic><topic>chronic hepatitis</topic><topic>Europe</topic><topic>Hepacivirus - genetics</topic><topic>Hepacivirus - immunology</topic><topic>Hepatitis B - drug therapy</topic><topic>Hepatitis B - genetics</topic><topic>Hepatitis B - immunology</topic><topic>hepatitis B virus</topic><topic>Hepatitis B, Chronic - drug therapy</topic><topic>Hepatitis B, Chronic - genetics</topic><topic>Hepatitis B, Chronic - immunology</topic><topic>Hepatitis C virus</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Hepatitis C, Chronic - genetics</topic><topic>Hepatitis C, Chronic - immunology</topic><topic>Humans</topic><topic>Interferons - genetics</topic><topic>Interferons - immunology</topic><topic>Interferons - therapeutic use</topic><topic>Polyethylene Glycols - administration & dosage</topic><topic>Polyethylene Glycols - therapeutic use</topic><topic>Polymerase Chain Reaction</topic><topic>Ribavirin - administration & dosage</topic><topic>Ribavirin - therapeutic use</topic><topic>thymalfasin</topic><topic>Thymosin - analogs & derivatives</topic><topic>Thymosin - therapeutic use</topic><topic>Viral Vaccines - genetics</topic><topic>Viral Vaccines - immunology</topic><topic>Viral Vaccines - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ciancio, A.</creatorcontrib><creatorcontrib>Rizzetto, M.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Environment Abstracts</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>Environment Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of the New York Academy of Sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ciancio, A.</au><au>Rizzetto, M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Thymalfasin in the treatment of hepatitis B and C</atitle><jtitle>Annals of the New York Academy of Sciences</jtitle><addtitle>Ann N Y Acad Sci</addtitle><date>2010-05</date><risdate>2010</risdate><volume>1194</volume><issue>1</issue><spage>141</spage><epage>146</epage><pages>141-146</pages><issn>0077-8923</issn><eissn>1749-6632</eissn><coden>ANYAA9</coden><abstract>Thymalfasin exhibited an immunomodulatory and a direct antiviral mechanism of action. The low rate of sustained response of chronic hepatitis with current therapies, underscores the need for new therapeutic options. It has been suggested that thymalfasin may have efficacy in the treatment of chronic hepatitis B and C. Pilots studies in patients with chronic hepatitis B treated with thymalfasin in combination with interferon or nucleoside analogue, showed a 70% complete sustained response rate. Studies in chronic hepatitis C patients, would indicate that thymalfasin in combination with standard or pegylated interferon with ribavirin may improve response rate in hepatitis C virus (HCV) naïve and nonresponder patients. However, a large phase‐III randomized study conducted in Europe in HCV patients nonresponder to Peg‐interferon with ribavirin, demonstrated that thymalfasin did not improve the rate of sustained virologic responses, but, in patients who completed therapy, thymalfasin significantly diminished the relapse rate. In conclusion, thymalfasin, in combination with the standard of care, may be helpful as an adjuvant in the treatment of patients with chronic hepatitis B and C.</abstract><cop>Malden, USA</cop><pub>Blackwell Publishing Inc</pub><pmid>20536462</pmid><doi>10.1111/j.1749-6632.2010.05487.x</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0077-8923 |
| ispartof | Annals of the New York Academy of Sciences, 2010-05, Vol.1194 (1), p.141-146 |
| issn | 0077-8923 1749-6632 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_746085700 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adjuvants, Immunologic - genetics Adjuvants, Immunologic - therapeutic use Antiviral Agents - administration & dosage Antiviral Agents - immunology Antiviral Agents - therapeutic use antiviral treatment chronic hepatitis Europe Hepacivirus - genetics Hepacivirus - immunology Hepatitis B - drug therapy Hepatitis B - genetics Hepatitis B - immunology hepatitis B virus Hepatitis B, Chronic - drug therapy Hepatitis B, Chronic - genetics Hepatitis B, Chronic - immunology Hepatitis C virus Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - genetics Hepatitis C, Chronic - immunology Humans Interferons - genetics Interferons - immunology Interferons - therapeutic use Polyethylene Glycols - administration & dosage Polyethylene Glycols - therapeutic use Polymerase Chain Reaction Ribavirin - administration & dosage Ribavirin - therapeutic use thymalfasin Thymosin - analogs & derivatives Thymosin - therapeutic use Viral Vaccines - genetics Viral Vaccines - immunology Viral Vaccines - therapeutic use |
| title | Thymalfasin in the treatment of hepatitis B and C |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T06%3A06%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Thymalfasin%20in%20the%20treatment%20of%20hepatitis%20B%20and%20C&rft.jtitle=Annals%20of%20the%20New%20York%20Academy%20of%20Sciences&rft.au=Ciancio,%20A.&rft.date=2010-05&rft.volume=1194&rft.issue=1&rft.spage=141&rft.epage=146&rft.pages=141-146&rft.issn=0077-8923&rft.eissn=1749-6632&rft.coden=ANYAA9&rft_id=info:doi/10.1111/j.1749-6632.2010.05487.x&rft_dat=%3Cproquest_cross%3E746085700%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1553761976&rft_id=info:pmid/20536462&rfr_iscdi=true |